» Articles » PMID: 28379620

Genome-wide Copy Number Variation Pattern Analysis and a Classification Signature for Non-small Cell Lung Cancer

Overview
Date 2017 Apr 6
PMID 28379620
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

The accurate classification of non-small cell lung carcinoma (NSCLC) into lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) is essential for both clinical practice and lung cancer research. Although the standard WHO diagnosis of NSCLC on biopsy material is rapid and economic, more than 13% of NSCLC tumors in the USA are not further classified. The purpose of this study was to analyze the genome-wide pattern differences in copy number variations (CNVs) and to develop a CNV signature as an adjunct test for the routine histopathologic classification of NSCLCs. We investigated the genome-wide CNV differences between these two tumor types using three independent patient datasets. Approximately half of the genes examined exhibited significant differences between LUAD and LUSC tumors and the corresponding non-malignant tissues. A new classifier was developed to identify signature genes out of 20 000 genes. Thirty-three genes were identified as a CNV signature of NSCLC. Using only their CNV values, the classification model separated the LUADs from the LUSCs with an accuracy of 0.88 and 0.84, respectively, in the training and validation datasets. The same signature also classified NSCLC tumors from their corresponding non-malignant samples with an accuracy of 0.96 and 0.98, respectively. We also compared the CNV patterns of NSCLC tumors with those of histologically similar tumors arising at other sites, such as the breast, head, and neck, and four additional tumors. Of greater importance, the significant differences between these tumors may offer the possibility of identifying the origin of tumors whose origin is unknown.

Citing Articles

Proteogenomic analysis reveals non-small cell lung cancer subtypes predicting chromosome instability, and tumor microenvironment.

Song K, Choi S, Kim K, Hwang H, Chang E, Park J Nat Commun. 2024; 15(1):10164.

PMID: 39580524 PMC: 11585665. DOI: 10.1038/s41467-024-54434-4.


NKX2‑1 copy number alterations are associated with oncogenic, immunological and prognostic remodeling in non‑small cell lung cancer.

Luna H, Imasa M, Juat N, Hernandez K, Sayo T, Cristal-Luna G Oncol Lett. 2024; 28(1):303.

PMID: 38774453 PMC: 11106692. DOI: 10.3892/ol.2024.14436.


DNA variants detected in primary and metastatic lung adenocarcinoma: a case report and review of the literature.

Kelly C, Raymond C, Han S, Lin Y, Chen L, Huang G Lab Med. 2024; 55(5):658-662.

PMID: 38527227 PMC: 11371898. DOI: 10.1093/labmed/lmae019.


Assessment of MYC and TERT copy number variations in lung cancer using digital PCR.

Brik A, Wichert K, Weber D, Szafranski K, Rozynek P, Meier S BMC Res Notes. 2023; 16(1):279.

PMID: 37858127 PMC: 10585721. DOI: 10.1186/s13104-023-06566-x.


Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis.

Skakodub A, Walch H, Tringale K, Eichholz J, Imber B, Vasudevan H Nat Commun. 2023; 14(1):4980.

PMID: 37591896 PMC: 10435547. DOI: 10.1038/s41467-023-40793-x.


References
1.
Lin J, Sun T, Ji L, Deng W, Roth J, Minna J . Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene. 2007; 26(49):6989-96. PMC: 3457636. DOI: 10.1038/sj.onc.1210500. View

2.
Kang J, Koo S, Kwon K, Park J, Kim J . Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung. BMC Cancer. 2009; 9:237. PMC: 2716371. DOI: 10.1186/1471-2407-9-237. View

3.
Micke P, Mattsson J, Djureinovic D, Nodin B, Jirstrom K, Tran L . The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs. J Thorac Oncol. 2016; 11(6):862-72. DOI: 10.1016/j.jtho.2016.01.020. View

4.
Travis W, Rekhtman N . Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med. 2011; 32(1):22-31. DOI: 10.1055/s-0031-1272866. View

5.
Garnis C, Lockwood W, Vucic E, Ge Y, Girard L, Minna J . High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer. 2005; 118(6):1556-64. DOI: 10.1002/ijc.21491. View